Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals (ARWR)
NASDAQ:ARWR
RESEARCH TOOLSreports
Holding ARWR?
Track your performance easily
ARWR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$17.05 - $39.83
Previous Close$19.63
Volume250.65K
Average Volume (3M)1.44M
Market Cap
$2.43B
Enterprise Value$2.38B
Total Cash (Recent Filing)$578.28M
Total Debt (Recent Filing)$510.55M
Price to Earnings (P/E)―
Beta1.91
Next Earnings
Feb 05, 2025EPS Estimate
-$0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.00
Shares Outstanding124,434,442
10 Day Avg. Volume1,527,738
30 Day Avg. Volume1,437,110
Standard Deviation0.17
R-Squared0.08
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)13.17
Price to Sales (P/S)124.31
Price to Cash Flow (P/CF)-4.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue670.39
Enterprise Value/Gross Profit670.39
Enterprise Value/Ebitda-4.10
Forecast
1Y Price Target
$40.90Price Target Upside109.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Arrowhead Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessFazirsiran demonstrated dose-dependent reductions in serum Z-ATT, reaching significant levels at the Phase 3 dose, indicating promising trial results.
Financial StrengthArrowhead Pharmaceuticals secured a $500M strategic financing facility with a flexible 7-year repayment structure, providing substantial financial support for its key portfolio priorities.
Strategic PartnershipThe partnership with SRPT provides a significant cash infusion of over $1.1 billion, strengthening the company's balance sheet for future milestones.
Bears Say
Financial PerformanceThe recent equity sell-off was driven by relatively expensive debt financing and higher than expected R&D spending, which increased manufacturing and clinical trial costs.
Market OutlookTAK's sales expectations for fazirsiran fall below projections, reflecting a more cautious outlook on market penetration.
Product DevelopmentArrowhead announced it will not pursue further development of ARO-MUC5AC due to the inability to reliably assess the primary target engagement biomarker.
---
Ownership Overview
4.57% Insiders
20.72% Mutual Funds
23.22% Other Institutional Investors
26.54% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARWR FAQ
What was Arrowhead Pharmaceuticals’s price range in the past 12 months?
Arrowhead Pharmaceuticals lowest stock price was $17.05 and its highest was $39.83 in the past 12 months.
What is Arrowhead Pharmaceuticals’s market cap?
Currently, no data Available
When is Arrowhead Pharmaceuticals’s upcoming earnings report date?
Arrowhead Pharmaceuticals’s upcoming earnings report date is Feb 05, 2025 which is in 41 days.
How were Arrowhead Pharmaceuticals’s earnings last quarter?
Arrowhead Pharmaceuticals released its earnings results on Nov 26, 2024. The company reported -$1.36 earnings per share for the quarter, missing the consensus estimate of -$1.12 by -$0.24.
Is Arrowhead Pharmaceuticals overvalued?
According to Wall Street analysts Arrowhead Pharmaceuticals’s price is currently Undervalued.
Does Arrowhead Pharmaceuticals pay dividends?
Arrowhead Pharmaceuticals does not currently pay dividends.
What is Arrowhead Pharmaceuticals’s EPS estimate?
Arrowhead Pharmaceuticals’s EPS estimate is -$0.41.
How many shares outstanding does Arrowhead Pharmaceuticals have?
Arrowhead Pharmaceuticals has 124,434,440 shares outstanding.
What happened to Arrowhead Pharmaceuticals’s price movement after its last earnings report?
Arrowhead Pharmaceuticals reported an EPS of -$1.36 in its last earnings report, missing expectations of -$1.12. Following the earnings report the stock price went up 24.228%.
Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals?
Among the largest hedge funds holding Arrowhead Pharmaceuticals’s share is Slate Path Capital LP. It holds Arrowhead Pharmaceuticals’s shares valued at 95M.
---
Arrowhead Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$40.90 (109.10% Upside)
$40.90 (109.10% Upside)
Blogger Sentiment
Bullish
ARWR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 907.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.32%
12-Months-Change
Fundamentals
Return on Equity
-262.48%
Trailing 12-Months
Asset Growth
48.89%
Trailing 12-Months
Company Description
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
---
ARWR Earnings Call
Q4 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected a strong focus on strategic growth and clinical advancements for Arrowhead, particularly through plozasiran's promising results and pipeline expansion. However, financial challenges remain with increased losses and R&D expenses, balanced by strategic financing efforts.Read More>---
ARWR Stock 12 Month Forecast
Average Price Target
$40.90
▲(109.10% Upside)
Technical Analysis
Alnylam Pharma
―
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
Voyager Therapeutics
―
Best Analysts Covering ARWR
1 Year
1 Year Success Rate
19/39 ratings generated profit
1 Year Average Return
+30.54%
reiterated a buy rating 16 days ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 48.72% of your transactions generating a profit, with an average return of +30.54% per trade.
---